BioSolution Designs and RoosterBio Announce Ongoing Collaboration on Genetically Modified MSCs for Biotherapeutic Development; Companies Hope to “Accelerate the Clinical Progression of the Next Generation of Cell and Exosome Therapeutics”

On May 2, 2024, BioSolution Designs (BSD), a biotechnology invention studio developing proprietary platforms for multigenic gene and cell therapies, announced its ongoing strategic collaboration with RoosterBio, a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services. This partnership leverages BSD’s multigenic design and assembly platform, Bird of PreyTM, and cell engineering expertise along with RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services to simplify the development and manufacturing of engineered MSC-derived therapies. Together, BSD and RoosterBio deliver an end-to-end solution for the engineering and development of cell- and exosome-based therapeutics, including BSD’s genetic engineering expertise and RoosterBio’s critical raw materials, expert process development, and advanced analytical characterization. Both teams have proven capabilities to deliver engineered therapies that possess a favorable global regulatory profile.

Login Or Register To Read Full Story